SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

PRIME is the native token of the Echelon Prime Foundation, a Web3 ecosystem advancing the next generation of gaming. Echelon creates and distributes tools to encourage innovation in, and promote the growth of, novel gaming models and economies. The first game to adopt and utilize PRIME is Parallel, a sci-fi trading card game.

Echelon Prime

Echelon Prime is trending as traders speculate on a major reversal, fueled by optimism surrounding the broader altcoin market and the platform's role in the growing Web3 gaming economy. The community is actively discussing potential price floors and long-term targets, with many viewing current volume levels as a prime accumulation phase for a projected breakout.

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

NIGHT is currently attracting significant community attention as it prepares for its mainnet launch, with investors debating the balance between the project's institutional-grade privacy goals and concerns regarding its decentralization and ties to Google Cloud. While some traders are bullish on its long-term potential within the Cardano ecosystem, others are actively discussing airdrop unlock schedules, technical support levels, and the project's ongoing regulatory compliance narrative.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is experiencing intense trading activity as retail participants leverage social media and community sentiment to fuel rapid price fluctuations and coordinate 'leg ups'. While some holders remain highly bullish on the potential for multi-week growth and repeat runs, critics frequently point to the pattern as a classic high-risk pump-and-dump scheme characterized by extreme volatility.

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Take-Two Interactive is currently trending as investors grapple with the company's decision to delay the highly anticipated release of Grand Theft Auto VI, a move that has sparked widespread community debate regarding institutional selling and insider trading allegations. Despite the near-term volatility and frustration over the revised timeline, many long-term shareholders remain bullish, viewing the current price action as a strategic buying opportunity ahead of an eventual massive marketing push and the title's long-term revenue potential.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors gear up for the upcoming presentation of long-term Week 40 clinical data at the AAD conference, which is being closely watched as a pivotal catalyst for the stock. The community is actively discussing Sonelokimab's potential to establish itself as a best-in-class treatment for Hidradenitis Suppurativa, with many pointing to recent analyst upgrades and continued institutional accumulation as signs of significant upside potential despite recent price volatility.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing increased community chatter as traders track the upcoming Goliath Layer-1 blockchain mainnet launch. While some investors emphasize the network's potential for institutional DeFi and programmable payments, others remain cautious, debating whether recent price action represents genuine accumulation or another cyclical pump-and-dump setup.

Iridium Communications, Inc. operates as a commercial provider of communications services offering true global coverage, connecting people, organizations and assets to and from anywhere, in real time. It offers its services to businesses, the U.S. and foreign governments, non-governmental organizations, and consumers via satellite network, which has an architecture of operational satellites with in-orbit spares and related ground infrastructure. Its products include personal communicators, messengers, and trackers, satellite phones, push-to-talk-devices, broadband terminals, midband terminals, external antennas, docking stations, apps, accessories and developer tools & resources. The company was founded in 2000 and is headquartered in McLean, VA.

Iridium Communications Inc

Iridium Communications is experiencing significant community interest and market volatility, fueled by its ongoing expansion into satellite-based time and location (STL) services following its recent acquisition of Satelles. Investors are closely monitoring the stock's valuation and technical support levels ahead of upcoming earnings, with active discussions focused on its defense contracts, share buyback initiatives, and how it differentiates itself from other satellite competitors.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpool is facing intense selling pressure following a disappointing quarterly report that included a dividend cut and lowered forward guidance, fueling concerns over demand softness and competitive headwinds. Investors are actively debating whether the stocks current valuation represents a deep-value opportunity or a continued downward spiral as they weigh the companys structural challenges against its historical role as a cyclical leader in the housing sector.

Direxion Shares ETF Trust - Direxion Daily Gold Miners Index Bull 2X ETF

Direxion Daily Gold Miners Index Bull 2X Shares

NUGT is experiencing intense community focus as traders debate the sustainability of gold's record-breaking rally, with many highlighting leveraged opportunities amidst geopolitical uncertainty and central bank accumulation. While some participants are wary of signs of an overbought market and potential technical corrections, others remain bullish on the long-term potential for miners to outperform as a hedge against currency debasement and broader economic instability.

Direxion Shares ETF Trust - Direxion Daily S&P 500 Bull 3X ETF

Direxion Daily S&P 500 Bull 3X Shares

The SPXL is seeing heavy volatility as investors debate whether current market conditions represent a buying opportunity or a deeper correction driven by escalating geopolitical tensions and institutional liquidity concerns. Community sentiment remains polarized, with many traders leveraging the S&P 500's movement through algorithmic signals and triple-leveraged ETFs, while others warn of potential downside risks if current support levels break.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Promising Biotech Stocks To Keep An Eye On - December 9th

WAVE Life Sciences, Exicure, argenex, Danaher, Senti Biosciences, Abivax, and Vertex Pharmaceuticals are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool...

<ul class="summary-bullets"><li>Phase 2 data showed rapid increases in CD34+ stem cells, allowing same-day dosing and collection.</li><li>Daratumumab-treated patients, who often struggle with mobilization, also achieved strong collection outcomes.</li><li>The treatment was well tolerated, with no burixafor-related side effects above Grade 2 reported in the study.</li></ul>Shares of Exicure Inc. (XCUR) surged nearly 40% on Tuesday after the company reported encouraging Phase 2 results for its experimental stem cell mobilization drug burixafor (GPC-100).&nbsp;The findings, shared at the American Society of Hematology meeting in Orlando, focused on patients with multiple myeloma preparing for autologous stem cell transplant.<h2 class="st-heading-2">Trial Meets Primary Endpoint</h2>The open-label, multicenter study found that 17 of 19 patients reached the trial’s stem cell collection target within two sessions. Two additional patients reached the target after an extra session.Among participants who proceeded to transplant, median neutrophil engraftment occurred in 13 days and platelet engraftment in 17.5 days. Exicure said burixafor worked quickly, boosting CD34+ stem cells, the cells doctors need to collect for transplant, within about an hour. The company said that the rapid rise makes it possible to give the drug and collect the cells on the same day.<h2 class="st-heading-2">Activity In Daratumumab-Exposed Patients</h2>Sixteen of 19 patients had previously received daratumumab, a therapy linked to reduced stem cell yield. Of these, 14 patients met the primary endpoint, including 12 of 14 who had also been treated with lenalidomide.Longer intervals between the last daratumumab dose and leukapheresis were associated with higher CD34+ cell yields.<h2 class="st-heading-2">Safety Findings</h2>The regimen of burixafor, propranolol, and G-CSF was well tolerated, with no adverse events above Grade 2 attributed to burixafor.“In this Phase 2 study, the combination of burixafor, G-CSF and propranolol showed an excellent safety profile and supported reliable mobilization of hematopoietic progenitor cells,” said lead investigator Jack Khouri of the Cleveland Clinic, adding that rapid cell mobilization may reduce the burden of the process for patients.<h2 class="st-heading-2">Pipeline Expansion Plans</h2>Burixafor, a selective CXCR4 antagonist acquired through Exicure’s January purchase of GPCR Therapeutics’ assets, is also being evaluated in sickle cell disease, rare transplant-eligible disorders, and cell and gene therapy settings.Exicure said a chemosensitization study in acute myeloid leukemia is planned, based on the drug’s ability to mobilize malignant cells from the bone marrow into peripheral blood.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Exicure was ‘extremely bullish’ amid ‘extremely high’ message volume. One user said, “Wow! This candle is showing a strong bullish setup. A powerful pump is coming.”<stembedurl>https://stocktwits.com/OmidArefi/message/638609203</stembedurl><figure class="image"><img style="aspect-ratio:968/141;" src="https://news.stocktwits-cdn.com/xcur_ss_png_95a0e0eba0.webp" alt="xcur ss.png" width="968" height="141"><figcaption>XCUR sentiment and message volume as of December 9| Source: Stocktwits</figcaption></figure>Another user called the stock cheap at the current price, “considering the data!”<stembedurl>https://stocktwits.com/Notoriousinvestor/message/638601332</stembedurl><a href="https://stocktwits.com/symbol/XCUR">Exicure’s stock</a> has declined 45% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Exicure’s stock (XCUR) has declined 45% so far in 2025. (Photo credit: Getty Images)

Exicure Stock Soars 40% After Stem Cell Drug Helps Most Patients Hit Phase 2 Goal — Traders Call It ‘Cheap’ At Current Levels

The company's stem cell drug burixafor helped nearly 90% of patients meet the Phase 2 goal.

Equity

Exicure, Inc. Loss At -$2.44 Mln In Q3

(RTTNews) - Exicure, Inc. (XCUR) reported Loss for third quarter of -$2.44 million...

Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Exicure, Inc. (NASDAQ: XCUR) breached their fiduciary duties to shareholders. If you...

Shares of Exicure Inc. surged more than 25% on Thursday, reaching levels last seen over three weeks ago, following the announcement of a strategic acquisition and collaboration deal with South Korea-based GPCR Therapeutics.Exicure revealed it has agreed to purchase all shares of GPCR Therapeutics USA, the California-based subsidiary of GPCR Therapeutics.&nbsp;As part of the agreement, Exicure and GPCR have entered into a licensing and collaboration arrangement to advance and commercialize GPCR-related technologies.While financial terms of the acquisition were not disclosed, Exicure outlined that the deal includes milestone payments to GPCR Therapeutics tied to clinical trial progress, marketing approvals, and net sales achievements.&nbsp;Additionally, Exicure will pay a recurring royalty of at least 10% of net sales derived from the licensed technologies.Retail interest surged after the announcement, with Exicure’s message volume on Stocktwits spiking, placing the ticker among the top 10 trending symbols on the platform.<stembedurl>https://stocktwits.com/topstockalerts/message/601124689</stembedurl><stembedurl>https://stocktwits.com/Pippi_Langstrumpf66/message/601121735</stembedurl>GPCR USA is noted for its work in developing cutting-edge treatments, including Opdivo, a widely used autoimmune disease therapy generating about $10 billion in annual revenue.&nbsp;The company is also behind Yervoy, the first FDA-approved treatment for lung cancer.&nbsp;Currently, GPCR USA is conducting a Phase 2 clinical trial targeting blood cancer patients, focusing on those requiring hematopoietic stem cell transplantation (HSCT) for conditions like multiple myeloma.Exicure’s stock has been a standout performer, gaining 265% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Exicure Stock Soars Over 25% On Acquisition Of GPCR Therapeutics’ U.S. Unit: Retail Chatter Spikes 

GPCR USA is noted for its work in developing cutting-edge treatments, including Opdivo, a widely used autoimmune disease therapy generating about $10 billion in annual revenue.

Micro-cap early-stage biotech Exicure, Inc.’s ($XCUR) shares rose sharply in premarket trading on Friday following a deal to acquire a cancer drug pipeline from a South Korean company.The company announcement late Thursday that it had signed a memorandum of understanding with GPCR Therapeutics on Dec. 24 to acquire the latter’s US subsidiary. The agreement also provides for technology transfer and collaborative research on GPCR’s other ongoing drug development pipelines.Chicago-based Exicure said it intends to receive technology transfer for GPCR Therapeutics’ CXCR4 inhibitor, which is in Phase 2 development, along with its related patents and intellectual property.&nbsp;The company views the proposed acquisition as a means to advance as a clinical-stage biotech. It plans to finalize the ongoing clinical trials involving stem cell mobilizers in multiple myeloma patients and prepare clinical studies related to acute myeloid leukemia.&nbsp;Excurire said the market potential for the two blood cancer types is around $1 billion to $2 billion annually.The company also plans to collaborate on R&amp;D in GPCR’s ongoing research in immuno-oncology, fibrosis treatments, and obesity therapies.&nbsp;South Korean drug company GPCR specializes in GPCR (G Protein-Coupled Receptor), representing over one-third of all drug targets. The company has secured target patents around prominent GPCRs such as CXCR4. It possesses multiple pipelines addressing blood cancers and solid tumors, genetic disorders, idiopathic pulmonary fibrosis, and obesity, including ongoing Phase 2 trials in the U.S. for multiple myeloma.&nbsp;Exicure said the deal will be funded from the $14 million capital investments it recently secured in three transactions.&nbsp;In an 8-K filing with the SEC, Exicure said the Nasdaq has notified that the company has met all requirements for continued listing on the exchange.A Stocktwits watcher pointed to the stock's low float and predicted a sharp move on the news.<stembedurl>https://stocktwits.com/SBW_Trades/message/597953319</stembedurl>In premarket trading, Exicure stock was up 8.41% at $18.70 at 7:05 a.m.ET. The stock has gained nearly 500% for the year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/5-media-and-entertainment-and-communication-services-stocks-that-gained-massive-retail-following-on-stocktwits-in-2024/cJO7BR7RjM">5 Media &amp; Entertainment And Communication Services Stocks That Gained Massive Retail Following On Stocktwits in 2024</a>

Woman examining laboratory samples - stock photo | Image source: Getty Images

Exicure Stock Surges On Blood Cancer Portfolio Acquisition Plans, Nasdaq Compliance: Retail Exuberant

Chicago-based Exicure said it intends to receive technology transfer for GPCR Therapeutics’ CXCR4 inhibitor, along with its related patents and intellectual property. 

Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The firm's product pipeline includes Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Redwood City, CA.

Exicure Inc

Peloswing

JFDI

ACInvestorBlog

GPaisa

A pillar of the Stocktwits ecosystem. This award recognizes the member who fosters connection, shares invaluable insights, and elevates the daily discussion to empower their fellow traders, on-platform.

Current Price	$4.42
Prev Close	$4.61
Open	$4.46
Dividend Yield	0.00%
50-Day Moving Average	$4.39
Beta	0.30
Avg. Volume	27,174.26
PE Ratio	-5.75

52-Week High	$14.11
52-Week Low	$3.10
Market Capitalization	$28.14M
EPS (Annual)	-$0.7854
Price to Book	7.17
Revenue Per Employee	$0.00

XCUR
Exicure Inc

Feed

News

Sentiment

Fundamentals

Info

Latest XCUR News

XCURExicure Inc